|
1) Fuster V, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation. Circulation. 2006; 114: e257-354
|
|
|
|
2) Burstein B, et al. Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. J Am Coll Cardiol. 2008; 51: 802-9
|
|
|
|
|
|
3) Li D, et al. Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. Circulation. 1999; 100: 87-95
|
|
|
|
|
|
4) Manabe I, et al. Gene expression in fibroblasts and fibrosis: involvement in cardiac hypertrophy. Circ Res. 2002; 91: 1103-13
|
|
|
|
|
|
5) Nakajima H, et al. Atrial but not ventricular fibrosis in mice expressing a mutant transforming growth factor-beta(1)transgene in the heart. Circ Res. 2000; 86: 571-9
|
|
|
|
|
|
6) Verheule S, et al. Increased vulnerability to atrial fibrillation in transgenic mice with selective atrial fibrosis caused by overexpression of TGF-beta1. Circ Res. 2004; 94: 1458-65
|
|
|
|
|
|
7) Ommen SR, et al. Atrial arrhythmias after cardio-thoracic surgery. N Engl J Med. 1997; 336: 1429-34
|
|
|
|
|
|
8) Frustaci A, et al. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation. 1997; 96: 1180-4
|
|
|
|
|
|
9) Yamashita T, et al. Recruitment of immune cells across atrial endocardium in human atrial fibrillation. Circ J. 2010; 74: 262-70
|
|
|
|
|
10) Kumagai K, et al. The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model. Cardiovasc Res. 2004; 62: 105-11
|
|
|
|
|
|
11) Engelmann MD, et al. Inflammation in the genesis and perpetuation of atrial fibrillation. Eur Heart J. 2005; 26: 2083-92
|
|
|
|
|
|
12) Issac TT, et al. Role of inflammation in initiation and perpetuation of atrial fibrillation: a systematic review of the published data. J Am Coll Cardiol. 2007; 50: 2021-8
|
|
|
|
|
|
13) Chung MK, et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation. 2001; 104: 2886-91
|
|
|
|
|
|
14) Metz M, et al. Mast cells in the promotion and limitation of chronic inflammation. Immunol Rev. 2007; 217: 304-28
|
|
|
|
|
|
15) Sperr WR, et al. The human cardiac mast cell: localization, isolation, phenotype, and functional characterization. Blood. 1994; 84: 3876-84
|
|
|
|
|
|
16) Sun J, et al. Mast cells promote atherosclerosis by releasing proinflammatory cytokines. Nat Med. 2007; 13: 719-24
|
|
|
|
|
|
17) Bot I, et al. Perivascular mast cells promote atherogenesis and induce plaque destabilization in apolipoprotein E-deficient mice. Circulation. 2007; 115: 2516-25
|
|
|
|
|
|
18) Sun J, et al. Mast cells modulate the pathogenesis of elastase-induced abdominal aortic aneurysms in mice. J Clin Invest. 2007; 117: 3359-68
|
|
|
|
|
|
19) Tsuruda T, et al. Adventitial mast cells contribute to pathogenesis in the progression of abdominal aortic aneurysm. Circ Res. 2008; 102: 1368-77
|
|
|
|
|
|
20) Hara M, et al. Evidence for a role of mast cells in the evolution to congestive heart failure. J Exp Med. 2002; 195: 375-81
|
|
|
|
|
|
21) Higuchi H, et al. Mast cells play a critical role in the pathogenesis of viral myocarditis. Circulation. 2008; 118: 363-72
|
|
|
|
|
|
22) Mackins CJ, et al. Cardiac mast cell-derived renin promotes local angiotensin formation, norepinephrine release, and arrhythmias in ischemia/reperfusion. J Clin Invest. 2006; 116: 1063-70
|
|
|
|
|
|
23) Kalesnikoff J, et al. New developments in mast cell biology. Nat Immunol. 2008; 9: 1215-23
|
|
|
|
|
|
24) Liao CH, et al. Cardiac mast cells cause atrial fibrillation through PDGF-A-mediated fibrosis in pressure-overloaded mouse hearts. J Clin Invest. 2010; 120: 242-53
|
|
|
|
|
|
25) Disertori M, et al. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med. 2009; 360: 1606-17
|
|
|
|
|